Skip to main content
Erschienen in: PharmacoEconomics 8/2016

01.08.2016 | Current Opinion

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges

verfasst von: Sevan Dirmesropian, James G. Wood, C. Raina MacIntyre, Philippe Beutels, Anthony T. Newall

Erschienen in: PharmacoEconomics | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

High-income countries are undergoing demographic transitions towards populations with substantial larger proportions of older adults. Due to the increased susceptibility of older adults to infectious diseases and their consequences, vaccination programmes are an important health intervention to help maintain healthy ageing. While much of the existing literature suggests that current vaccination programmes targeted at older adults and the elderly are likely to be cost effective in high-income countries, we argue that it is important to more fully consider some important issues and challenges. Since the majority of vaccines have been developed for children, economic evaluations of vaccination programmes have consequentially tended to focus on this age group and on how to incorporate herd-immunity effects. While programmes targeted at older adults and the elderly may also induce some herd effects, there are other important challenges to consider in these economic evaluations. For example, age and time effects in relation to vaccine efficacy and duration of immunity, as well as heterogeneity between targeted individuals in terms of risk of infection, severity of disease and response to vaccination. For some pathogens, there is also the potential for interactions with childhood programmes in the form of herd-immunity effects.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff (Millwood). 2000;19(3):191–203.CrossRefPubMed Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff (Millwood). 2000;19(3):191–203.CrossRefPubMed
3.
Zurück zum Zitat Schoen C, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Project Hope). 2009;28(6):w1171–83.CrossRef Schoen C, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Project Hope). 2009;28(6):w1171–83.CrossRef
6.
Zurück zum Zitat Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156(5–6):130–41.CrossRefPubMed Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156(5–6):130–41.CrossRefPubMed
7.
Zurück zum Zitat Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013. Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013.
9.
Zurück zum Zitat Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
10.
Zurück zum Zitat Esposito S, et al. Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med. 2014;25(3):203–12.CrossRefPubMed Esposito S, et al. Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med. 2014;25(3):203–12.CrossRefPubMed
11.
Zurück zum Zitat Kimman TG, et al. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.CrossRefPubMed Kimman TG, et al. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.CrossRefPubMed
14.
Zurück zum Zitat National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013. National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013.
15.
Zurück zum Zitat Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30(8):647–60.CrossRefPubMed Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30(8):647–60.CrossRefPubMed
16.
Zurück zum Zitat Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.CrossRefPubMed Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.CrossRefPubMed
18.
Zurück zum Zitat Ogilvie I, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.CrossRefPubMed Ogilvie I, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.CrossRefPubMed
19.
Zurück zum Zitat Postma MJ, et al. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconom Outcomes Res. 2006;6(2):215–27.CrossRef Postma MJ, et al. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconom Outcomes Res. 2006;6(2):215–27.CrossRef
20.
Zurück zum Zitat Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31(2):125–36.CrossRefPubMed Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31(2):125–36.CrossRefPubMed
21.
Zurück zum Zitat Newall AT, et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.CrossRefPubMed Newall AT, et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.CrossRefPubMed
22.
23.
Zurück zum Zitat Grutters JPC, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31(2):111–23.CrossRefPubMed Grutters JPC, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31(2):111–23.CrossRefPubMed
25.
Zurück zum Zitat Grigsby JS. The meaning of heterogeneity: an introduction. Gerontologist. 1996;36(2):145–6.CrossRefPubMed Grigsby JS. The meaning of heterogeneity: an introduction. Gerontologist. 1996;36(2):145–6.CrossRefPubMed
26.
Zurück zum Zitat Lelic A, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076.CrossRefPubMedPubMedCentral Lelic A, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.CrossRefPubMed Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.CrossRefPubMed
28.
Zurück zum Zitat Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60.CrossRefPubMed Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60.CrossRefPubMed
29.
Zurück zum Zitat Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388). Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388).
30.
Zurück zum Zitat Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed
31.
Zurück zum Zitat Ultsch B, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.CrossRefPubMedPubMedCentral Ultsch B, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108(1):1–7.CrossRefPubMed Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108(1):1–7.CrossRefPubMed
35.
Zurück zum Zitat Schmader KE, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentral Schmader KE, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbid. 2011;1:28–44.CrossRef Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbid. 2011;1:28–44.CrossRef
37.
Zurück zum Zitat Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422. Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422.
38.
Zurück zum Zitat Marengoni A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.CrossRefPubMed Marengoni A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.CrossRefPubMed
39.
Zurück zum Zitat Constans T, Alix E, Dardaine V. Protein-calorie malnutrition in the elderly: diagnostic methods and epidemiology [in French]. Presse Med. 2000;29(39):2171–6.PubMed Constans T, Alix E, Dardaine V. Protein-calorie malnutrition in the elderly: diagnostic methods and epidemiology [in French]. Presse Med. 2000;29(39):2171–6.PubMed
40.
42.
Zurück zum Zitat Mitnitski A, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(12):2184–9.CrossRefPubMed Mitnitski A, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(12):2184–9.CrossRefPubMed
43.
Zurück zum Zitat Rockwood K, et al. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.CrossRefPubMed Rockwood K, et al. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.CrossRefPubMed
44.
Zurück zum Zitat Ridda I, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27(10):1628–36.CrossRefPubMed Ridda I, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27(10):1628–36.CrossRefPubMed
45.
Zurück zum Zitat Yao X, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–21.CrossRefPubMedPubMedCentral Yao X, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–21.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5. MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5.
47.
Zurück zum Zitat Ridda I, et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin. 2007;3(3):83–6.CrossRefPubMed Ridda I, et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin. 2007;3(3):83–6.CrossRefPubMed
48.
Zurück zum Zitat Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015). Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015).
49.
Zurück zum Zitat Sisk JE, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.CrossRefPubMed Sisk JE, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.CrossRefPubMed
50.
Zurück zum Zitat Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.CrossRefPubMed Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.CrossRefPubMed
51.
Zurück zum Zitat Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc. 2005;294(16):2043–51.CrossRef Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc. 2005;294(16):2043–51.CrossRef
52.
Zurück zum Zitat Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–3.CrossRefPubMed Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–3.CrossRefPubMed
53.
Zurück zum Zitat Prince MJ, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.CrossRefPubMed Prince MJ, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.CrossRefPubMed
54.
Zurück zum Zitat Lang PO, et al. Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011;68(4):322–30.CrossRefPubMed Lang PO, et al. Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011;68(4):322–30.CrossRefPubMed
55.
Zurück zum Zitat Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81. Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81.
56.
Zurück zum Zitat Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
57.
Zurück zum Zitat Pradas R, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13(1):175.CrossRefPubMedPubMedCentral Pradas R, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13(1):175.CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMed Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMed
59.
Zurück zum Zitat Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.CrossRefPubMed Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.CrossRefPubMed
60.
Zurück zum Zitat Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208.CrossRefPubMed Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208.CrossRefPubMed
61.
Zurück zum Zitat Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMed Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMed
62.
Zurück zum Zitat Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84.
63.
Zurück zum Zitat Andrews RM, et al. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. Commun Dis Intell Q Rep. 2005;29(3):283–8.PubMed Andrews RM, et al. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. Commun Dis Intell Q Rep. 2005;29(3):283–8.PubMed
64.
Zurück zum Zitat Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.CrossRefPubMed Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.CrossRefPubMed
66.
Zurück zum Zitat Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prevent Med. 2014;69:224–34.CrossRef Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prevent Med. 2014;69:224–34.CrossRef
67.
Zurück zum Zitat Ridda I, et al. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient’s perception, attitude, and knowledge. Vaccine. 2008;26(2):234–40.CrossRefPubMed Ridda I, et al. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient’s perception, attitude, and knowledge. Vaccine. 2008;26(2):234–40.CrossRefPubMed
69.
Zurück zum Zitat Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.CrossRefPubMed Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.CrossRefPubMed
70.
Zurück zum Zitat Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91. Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91.
71.
Zurück zum Zitat Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005;29(2):136–42.CrossRefPubMed Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005;29(2):136–42.CrossRefPubMed
72.
74.
75.
Zurück zum Zitat Rocklöv J, Forsberg B, Meister K. Winter mortality modifies the heat-mortality association the following summer. Eur Respir J. 2009;33(2):245–51.CrossRefPubMed Rocklöv J, Forsberg B, Meister K. Winter mortality modifies the heat-mortality association the following summer. Eur Respir J. 2009;33(2):245–51.CrossRefPubMed
76.
Zurück zum Zitat Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94.CrossRefPubMed Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94.CrossRefPubMed
77.
78.
Zurück zum Zitat Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011. Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011.
79.
Zurück zum Zitat Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):0381–91.CrossRef Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):0381–91.CrossRef
80.
Zurück zum Zitat Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–83.CrossRefPubMed Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–83.CrossRefPubMed
81.
Zurück zum Zitat Chiu C, Dey A, Wang H. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34(Suppl):S1–167.CrossRef Chiu C, Dey A, Wang H. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34(Suppl):S1–167.CrossRef
82.
Zurück zum Zitat Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl. 1):S31–7.CrossRefPubMed Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl. 1):S31–7.CrossRefPubMed
Metadaten
Titel
Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges
verfasst von
Sevan Dirmesropian
James G. Wood
C. Raina MacIntyre
Philippe Beutels
Anthony T. Newall
Publikationsdatum
01.08.2016
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 8/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-016-0393-0

Weitere Artikel der Ausgabe 8/2016

PharmacoEconomics 8/2016 Zur Ausgabe